• linkedin
  • Increase Font
  • Sharebar

    Every New FDA Drug Approval in 2017

    The last 12 drugs approved in the year, along with the other 34.

     

    Calquence image

    CALQUENCE (acalabrutinib), AstraZeneca

    Indications: A kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

    Dosage: 100 mg orally approximately every 12 hours, with or without food. Advise patients not to break, open, or chew capsules. Manage toxicities using treatment interruption, dose reduction, or discontinuation.

    Contraindications: None.

    Click here to read the full label

    Previous ButtonNext Button

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available